Alemtuzumab in Multiple Sclerosis: Short- and Long-Term Effects of Immunodepletion on the Peripheral Treg Compartment-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Alemtuzumab in Multiple Sclerosis: Short- and Long-Term Effects of Immunodepletion on the Peripheral Treg Compartment

Published:2019-06-04 Issue: Volume:10 Page:
ISSN:1664-3224
Container-title:Frontiers in Immunology
language:
Short-container-title:Front. Immunol.

Author:

Haas Jürgen,Würthwein Cornelia,Korporal-Kuhnke Mirjam,Viehoever Andrea,Jarius Sven,Ruck Tobias,Pfeuffer Steffen,Meuth Sven G.,Wildemann Brigitte

Publisher

Frontiers Media SA

Subject

Immunology,Immunology and Allergy

Reference39 articles.

1. Alemtuzumab: a new therapy for active relapsing-remitting multiple sclerosis;Hartung;Mult Scler,2015

2. Alemtuzumab vs;Coles;N Engl J Med,2008

3. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial;Coles;Lancet,2012

4. Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 clinical trial;Coles;Neurology,2012

5. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial;Cohen;Lancet,2012

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Risk of secondary immune thrombocytopenia following alemtuzumab treatment for multiple sclerosis: a systematic review and meta-analysis;Frontiers in Neurology;2024-04-10

2. Distinct disease-modifying therapies are associated with different blood immune cell profiles in people with relapsing-remitting multiple sclerosis;International Immunopharmacology;2024-04

3. Immune reconstitution following alemtuzumab therapy is characterized by exhausted T cells, increased regulatory control of proinflammatory T cells and reduced B cell control;Frontiers in Immunology;2023-09-06

4. Smouldering Lesion in MS: Microglia, Lymphocytes and Pathobiochemical Mechanisms;International Journal of Molecular Sciences;2023-08-10

5. Distinct disease-modifying therapies are associated with different blood immune cell profiles in people with relapsing-remitting multiple sclerosis;2023-07-23

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3